Growth Stock Wire Investment Newsletter

 
Growth Stock Wire Investment Newsletter About Growth Stock Wire Frequently Asked Questions Growth Stock Wire Archives Contact Us Privacy Policy
Print Edition | Sponsored Link:

The End of the Blue Chip Bargains
by Graham Summers
September 29, 2006

For once, the mutual fund industry did us a favor.

I don’t mean to be brash, but generally I am not a fan of mutual funds. They rarely produce the excellent returns they promise and typically charge too much in fees and other expenses.

According to a study in Jeremy J. Siegel’s book Stocks For the Long Run, there were only three years between 1982 and 1992 when more than 50% of mutual funds beat the market. In fact, The Wall Street Journal reports that the average return for all mutual funds during this period was 16.3%. And the S&P 500? 17.5%.

However, in 2006, mutual funds created the rarest of opportunities for us: incredible market-leading businesses trading at bargain basement prices. It was enough to make you want to write a thank you note to Morgan Stanley, Fidelity, and Merrill Lynch.

Investor panic following the market corrections of May, June and July resulted in large quantities of capital leaving the U.S. marketplace. Nowhere is this more obvious than in U.S. stock-based mutual funds.

In June 2006, more than $8.4 billion flowed out of these funds. It was the first time money has left these investments in over three years. The last time was February 2003 when the market bottomed out following the tech bubble crash.

The result of this outflow of capital was that mutual funds had to diminish their positions in the stock market. Consequently, their investments of choice, blue chip stocks, hit their cheapest levels in years. These are the only companies liquid enough for large mutual funds to safely invest in. And they also happen to be the most profitable, stable companies in the world.

I’m talking about the Cokes, the Intels, the Johnson & Johnsons, even the General Electrics: the brand and market leaders of the world. I’m not simply picking these companies at random either. All of them were incredibly cheap this year. And all experienced significant insider buying.

50 years from now, people will still be drinking Coke, typing on their computers, wearing Band-Aids, and buying home appliances. And in the meantime those who invested in these companies this year will see their investments return anywhere from 10% to 20% a year.

If this doesn’t seem too impressive, consider that a 10% return compounded over a 20-year period comes to nearly a six-fold increase in your initial capital. A 20% return compounded over the same period comes to 37-fold increase.

This is how Warren Buffett became the second richest man in the world. As much as most financial writers like to write about Buffett’s inspiration from the Benjamin Graham School of value investing, in actuality Buffett made his fortune simply by investing in the best brands at the best possible prices.

As he put it, “I’d much rather buy a great company at a fair price than a fair company at a great price.” To that end, Buffett bought Coke in 1987 while it was trading around 40 times earnings and $4.00 a share. Today, 20 years later, Coke is above $40 and Buffett is a billionaire many times over.

We’ve discussed the mega-soft drink company in these pages before. So far Coke is up 11% for the year. It’s hardly budged in the face of several serious market corrections. The market has swung in favor of blue chip stocks… and this opportunity will not last forever.

As I write this, the mainstream financial media has begun to unveil its “Buy Blue Chip Stocks” banners. In other words, the end of the blue chip bargains is in sight and it’s time to look for the next big idea.

Good investing,

Graham

Icahn Seeks Control of ImClone
“Billionaire investor Carl Icahn, seeking to oust half the board and take control of ImClone Systems Inc., said he wants a new chief executive with biotechnology experience who can lead a more aggressive push to sell the cancer treatment Erbitux.

Icahn doesn't plan to renew efforts to sell the New York- based company, he said today in an interview. The 70-year-old investor is asking stockholders to dismiss Chairman David Kies and five other directors and to elect another Icahn ally to the board, giving him five of seven seats, according to a filing.”
Read On…


More strength in big pharma … Merck and Novartis at new highs for the year.

Volatility Index (VIX) still in the basement at below 12.

European ETFs at new highs … Spain, France, Netherlands, and Belgium.

In The News: Ichan seeks control of ImClone.
Last Change 52-Wk
S&P 500 1339.15 0.19% 10.05%
Oil (USO)* 56.65 -0.89% -16.49%
Gold (GLD)* 59.79 -0.03% 27.76%
Silver (SLV)* 115.41 -0.70% -16.44%
US Dollar 85.78 0.19% -4.06%
Euro 1.270 -0.13% 5.49%
VIX 11.72 1.21% -7.21%
^HUI 303.34 -0.76% 24.63%
10-year yield 4.63% 0.03 0.36
* Since ETF inception

Advertisement

Company Sym Industry

iShares Spain

EWP

Spanish stocks

iShares Belgium

EWK

Belgian stocks

iShares Europe

IEV

European stocks

iShares France

EWQ

French stocks

iShares Netherlands

EWN

Dutch stocks

Cash America

CSH

pawn shops

Dollar Financial

DLLR

pawn shops

General Motors

GM

automaker

General Mills

GIS

food

Gold Kist

GKIS

chickens

Merck

MRK

pharma

Novartis

NVS

pharma

Tripath Imaging

TPTH

cancer detection

Steve Madden

SHOO

shoes

Wolverine Worldwide

WWW

shoes

Enersis

ENI

utility

Coinstar

CSTR

coin counters

Reddy Ice

FRZ

ice

Knight Capital

NITE

asset mgmt.

Wendy's

WEN

fast food

Hasbro

HAS

toys

Insurance Port.

PIC

insurance ETF

Allstate

ALL

insurance

Align Technologies

ALGN

dental

Company Sym Industry

Advanced Analogic

AATI

semiconductors

Bassett Furniture

BSET

furniture

Advantage Energy

AAV

royalty trust

Holly Energy

HEP

pipelines

Hi-Tech Pharmacal

HITK

OTC drugs

VistaCare

VSTA

hospice services

Technical Olympic

TOA

homebuilder

Gravity

GRVY

online gaming

Home | About GSW | FAQ | GSW Archive | Privacy Policy | Contact Us

Customer Service: 1-888-261-2693 – Copyright 2008 Stansberry & Associates Investment Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This e-letter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry & Associates Investment Research, LLC. 1217 Saint Paul Street, Baltimore MD 21202